BIIL-260
BIIL-260 is a potent and long-acting orally active leukotriene B (4) receptor LTB4 antagonist, with anti-inflammatory activity. BIIL-260 interacts with the LTB4 receptor in a saturable, reversible, and competitive manner, has high affinity to the LTB4 receptor on isolated human neutrophil cell membranes with the Ki value of 1.7 nM[1].
Product Specifications
CAS Number
204974-93-6
UNSPSC
12352005
Target
Leukotriene Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/biil-260.html
Smiles
N=C(N)C1=CC=C(C=C1)OCC2=CC=CC(COC3=CC=C(C=C3)C(C4=CC=C(C=C4)O)(C)C)=C2
Molecular Formula
C30H30N2O3
Molecular Weight
466.57
References & Citations
[1]Birke FW, et al. In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B (4) receptor antagonist. J Pharmacol Exp Ther. 2001 Apr;297 (1) :458-66.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400883-100 1x 100 µL
PSA (Prostate Specific Antigen) (A67-B/E3), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
TRC-H414080-500MG 500 mg
4-(2-Hydroxyethyl)piperazine-1-carbaldehyde
Sign In for Pricing
View Details 
BNC742745-500 1x 500 µL
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2745), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details